India, Feb. 2 -- image credit- freepik

Global pharma major Lupin has announced a strategic collaboration with TB Alliance, a nonprofit drug developer, to advance the clinical development and commercialisation of the investigational drug Telacebec (formerly known as Q203), for the treatment of multiplemycobacterialdiseases including tuberculosis (TB), leprosy, and buruli ulcer.

Under the terms of the agreement, Lupin and TB Alliance will collaborate to support the clinical development and commercialisation of Telacebec, to provide advanced treatment options for patients affected by these diseases. TB Alliance will continue to lead the development process, while Lupin will provide its expertise in global manufacturing, regulatory affairs,...